The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome
The sulfonylurea drug gliquidone is FDA approved for the treatment of type 2 diabetes. Binding of gliquidone to ATP-sensitive potassium channels (SUR1, Kir6 subunit) in pancreatic β-cells increases insulin release to regulate blood glucose levels. Diabetes has been associated with increased levels o...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2021-10-01
|
| Seri Bilgileri: | Frontiers in Aging Neuroscience |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fnagi.2021.754123/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|